UK's NICE rejects the use of Kyprolis (carfilzomib)-based combination therapy in multiple myeloma- Amgen
The UK's National Institute for Health and Care Excellence has rejected the routine use of Kyprolis (carfilzomib), from Amgen, in combination with Revlimid (lenalidomide), from Celgene and dexamethasone, or dexamethasone, alone in patients with multiple myeloma who have had at least one prior therapy. Experts at NICE could not agree on a cost-effectiveness estimate, as modelling the costs was uncertain. In addition, Kyprolis failed to qualify for end-of-life consideration.
Comment: in the Phase III ASPIRE trial, patients receiving Kyprolis/Revlimid/dexamethasone had median progression-free survival of 26.3 months versus 17.6 months for those on Revlimid and dexamethasone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.